Hepatitis C Virus Infektion nach Lebertransplantation – Verlauf und erste Erfahrungen mit einer frühen antiviralen Kombinationstherapie mit Interferon alpha und Ribavirin

2015 ◽  
Vol 41 (08) ◽  
Author(s):  
M Schuchmann ◽  
G Greif-Higer ◽  
M Wunsch ◽  
C Mönch ◽  
AP Barreiros ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Interferon Alpha

Die chronische Hepatitis-C-Infektion: Häufigkeit, Verlauf und Stand der Behandlungsmöglichkeiten bei Patienten mit intravenöser Drogenabhängigkeit

2005 ◽  
Vol 51 (2) ◽  
pp. 97-108 ◽  
Author(s):  
Martin Schäfer ◽  
Thomas Berg
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Interferon Alpha ◽  
Prospektive Studien ◽  
Chronische Hepatitis ◽  
Chronische Hepatitis C

<B>Ziel:</B> Übersicht zur Problematik der chronischen Hepatitis-C-Virus-(HCV)-Infektion bei Patienten mit intravenöser Drogenabhängigkeit. </P><P><B>Methodik:</B> Zusammenfassung und Interpretation aktueller Studien zur Epidemiologie und Therapie. </P><P><B>Ergebnisse:</B> HCV-infizierte drogenabhängige Patienten werden häufig von einer Therapie mit (Peg)-Interferon-alpha und Ribavirin ausgeschlossen. Studien der letzten Jahre zeigen jedoch, dass insbesondere bei Patienten in Methadonsubstitution Heilungsraten erzielt werden können, die vergleichbar sind mit langfristigen Ansprechraten in Kollektiven ohne Suchterkrankung. </P><P><B>Schlussfolgerungen:</B> Chronisch HCV-infizierte Patienten mit einer Drogenabhängigkeit müssen bei individueller Therapieentscheidung und interdisziplinärer Betreuung nicht von einer antiviralen Therapie ausgeschlossen werden. Weitere prospektive Studien werden jedoch benötigt.

Funktion von CEACAM-1 im Rahmen der Therapie der Hepatitis C-Virus Infektion mit Interferon-alpha in vivo und in vitro

2006 ◽  
Vol 44 (08) ◽  
Author(s):  
P Hilgard ◽  
R Bröring ◽  
M Trippler ◽  
S Viazov ◽  
G Gerken ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Interferon Alpha

Hepatitis C Virus Infektion nach Lebertransplantation – Verlauf unter früher antiviraler Kombinationstherapie mit Interferon-alpha und Ribavirin

2006 ◽  
Vol 44 (08) ◽  
Author(s):  
T Zimmermann ◽  
AP Barreiros ◽  
G Greif-Higer ◽  
M Wörns ◽  
C Mönch ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Interferon Alpha

Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1

2016 ◽  
Vol 25 (1) ◽  
pp. 15-24 ◽  
Author(s):  
Tim Zimmermann ◽  
Dietrich Hueppe ◽  
Stefan Mauss ◽  
Peter Buggisch ◽  
Heike Pfeiffer-Vornkahl ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Interferon Alpha ◽  
Virological Response ◽  
Sustained Viral Response ◽  
Pegylated Interferon ◽  
Genotype 1 ◽  
Pegylated Interferon Alpha ◽  
Viral Response

Background & Aims: Smoking has multiple effects on factors influencing hepatitis C and antiviral therapy, including lipid metabolism, fibrosis, platelet count and adherence aspects. The aim of this analysis was to determine the impact of smoking on hepatitis C virus antiviral therapy. Methods: Data of two cohorts of an observational multicenter study including therapy-naïve patients infected with genotype 1 hepatitis C virus (HCV) treated with dual antiviral therapy (n=7,796) with pegylated interferon alpha 2a in combination with ribavirin, or triple antiviral therapy (n=1,122) containing telaprevir or boceprevir, were analysed. Results: In the univariate matched pair analysis of dual antiviral therapy patients (n=584), smoking was significantly associated with lower sustained viral response rates (p=0.026, OR 0.69 CI: 0.50 – 0.96). The effect of smoking on sustained viral response remained significant (p=0.028, OR 0.67 CI: 0.47 – 0.96) in the multivariate analysis when adjusting for all other baseline parameters with a significant association in the univariate analysis, i.e. diabetes, fibrosis, body mass index, transaminases and baseline viral load. Under protease inhibitors the influence of smoking on virological response did not arise. Conclusions: Smoking has a negative impact on antiviral therapy in naïve patients infected with HCV genotype 1 independently of age, gender, history of drug use or alcoholic liver disease. The effects of smoking might be overcome by the new antiviral agents.Abbreviations: APRI: AST to platelet ratio index; DAA: direct antiviral agent; DT: dual antiviral therapy; EoTR: end of treatment response; RVR: rapid virological response; EVR: early virological response; HCV: hepatitis C virus; IFN: interferon alpha; MPA: Matched Pair Analysis; NS: non-smokers; PEG-IFN: pegylated interferon alpha 2a; PI: protease inhibitor; RBV: ribavirin; SAE: serious adverse event; SOC: standard of care; S: smokers; SVR: sustained viral response.    

scholarly journals Hepatitis C Virus Clearance after Discontinuation of Pegylated Interferon Alpha-2a Monotherapy in a Child

2012 ◽  
Vol 2012 ◽  
pp. 1-4
Author(s):  
Takeshi Endo ◽  
Koichi Ito ◽  
Tokio Sugiura ◽  
Kenji Goto
Keyword(s):  
Hepatitis C Virus ◽  
Viral Load ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Interferon Alpha ◽  
Antiviral Treatment ◽  
Pegylated Interferon ◽  
Hcv Rna ◽  
Pegylated Interferon Alpha ◽  
Present Patient

The present patient was a 4-year-old boy. His hepatitis C virus genotype was 2a, and his viral load was high (1400,000 U/mL). The pretreatment liver biopsy revealed no fibrosis or malignancy and mild chronic hepatitis; his Knodell's histological activity (HAI) score was 4. Single nucleotide polymorphism of IL28B (rs8099917) was major type. The patient began antiviral treatment with pegylated interferon alpha 2a (90 μg/week). At week 9, serum HCV RNA became undetectable, with a sensitivity of 50 copies/mL. Antiviral treatment was discontinued at week 11 because the ALT level increased to 610 U/L. After discontinuation of therapy, the patient’s serum HCV RNA status became positive again. The serum viral load increased to 100,000 U/mL. During this period, he had been observed without medication. Sixteen months after stopping treatment, serum HCV became undetectable. Over a 4-year period, HCV RNA became negative and his anti-HCV antibody titer gradually decreased. In conclusion, though antiviral therapy resulted in failure or incomplete therapy, a reduced viral load resulted in viral clearance in the present patient. Interleukin 28B genotype might have association with the clearance of hepatitis C virus after discontinuation of antiviral therapy.

Sign in / Sign up

Export Citation Format

Share Document